We searched MEDLINE, Embase, and the Web of Science for studies from January, 1980, to April 30, 2015, with the terms “diabetes” or “T2D” or “T2DM” or “type 2 diabetes mellitus”, and “bone density”, “BMD”, “bone microarchitecture”, “osteopenia”, “osteoporosis”, or “fracture”. We also searched the reference lists of obtained studies and published reviews. In the selection and review of studies, we gave the greatest weight to systematic reviews and meta-analyses, or randomised controlled trials.
ReviewType 2 diabetes and the skeleton: new insights into sweet bones
Introduction
Diabetes is a chronic disease associated with substantial comorbidities. The widely recognised complications of this disease include neuropathy, nephropathy, and retinopathy, all of which can result in substantial morbidity, leading to recurrent admissions to hospital and increasing health-care costs. Notwithstanding, a very high prevalence of coexistent cardiovascular disease in patients with type 2 diabetes is the most serious comorbid disorder. Our patient in the case study (panel) has borderline hypertension, and only fair control of her diabetes, obesity, hypercholesterolaemia, and neuropathic changes. Targeted therapy should include control of the patient's lipids, reduction in blood pressure, and tightened glycaemic control. So what should be done, if anything, about this patient's two fractures and the likelihood that she might have increased skeletal fragility? On one hand, osteoporosis management in patients with type 2 diabetes frequently takes a back seat to the more life-threatening complications of middle-aged postmenopausal women for example heart disease and stroke. On the other hand, fractures can have a profound effect on quality of life and can lead to substantial disability. Although recent studies have provided some insight into the pathophysiology of skeletal fragility in diabetes,1, 2, 3 a considerable void is still present in our understanding of how obesity and diabetes affect the adult skeleton. In particular, defining the progression of bone changes during the evolution of this disease from prediabetes to overt diabetes through to insulin dependency will be essential when considering possible therapeutic interventions to mitigate skeletal fragility. Hence, now assessment of the bone disease associated with obesity, insulin resistance, microvascular disease, and type 2 diabetes is fully warranted.
Section snippets
Increased fracture risk in type 2 diabetes
Evidence accumulated during the past two decades suggests that type 2 diabetes is associated with up to a three times increased risk of hip and other non-vertebral fractures, depending on the skeletal site and disease severity.4, 5 For instance, the Health, Ageing, And Body Composition Study6 prospectively assessed incident non-traumatic fractures in community-dwelling men and women and reported that type 2 diabetes was associated with a 64% increase in fractures at all sites compared with
Structural and material contributions to diabetic skeletal fragility
A fracture occurs when the forces applied to a bone exceed its strength. Whole bone strength is determined by bone mass, bone microarchitecture and macroarchitecture, and the intrinsic properties of the bone matrix, such as the extent of mineralisation, collagen content, and the degree of collagen cross-linking.37 Increased fracture risk despite normal, or even increased, bone mass in people with type 2 diabetes implicates: (1) altered bone microarchitecture or deficits in bone material
Osteoblast function in type 2 diabetes
Type 2 diabetes is a disease of disordered glucose use and enhanced energy storage. In muscle and adipose tissue, insulin resistance is increased, such that insulin-mediated glucose uptake is impaired.49 This dysfunction is due to suppression of the glucose transporter, GLUT4, in muscle, resulting from changes in the signalling molecule, IRS1, fatty acid accumulation, and oxidative stress. In adipocytes, a similar process occurs and is associated with large fatty acid toxic effects. By
Pathophysiology of bone disease in type 2 diabetes: early stages of disease
The pathogenesis of diabetic skeletal fragility is multifactorial, and includes factors such as obesity, hyperinsulinaemia, hyperglycaemia, accumulation of AGEs, and presence of microvascular disease. These disorders are either counterbalanced or potentiated by each other and by other factors at various times in the natural history of the disease. As such, the pathophysiological changes of diabetic bone disease can be broadly discussed by separately considering the factors that affect the
Accelerated ageing, microvascular disease, and muscle dysfunction
Ageing is associated with the gradual accumulation of mitochondrial DNA alterations secondary to progressive oxidative damage. This process leads to impairment of respiratory chain complexes and an increased production of reactive oxygen species producing a cascade of deleterious metabolic events including the formation of AGEs. In addition to changing collagen structure, AGEs might interact with the receptor for advanced glycation end products on cell membranes, leading to increased oxidative
Pathophysiological model: bone metabolism throughout the evolution of diabetes
Although in the earlier discussion of this Review, we have attempted to broadly categorise bone disease into early and late phases of type 2 diabetes, this distinction is arbitrary and many of the pathophysiological factors, such as obesity, are often present throughout the course of type 2 diabetes. However, indirect evidence of the importance of the evolution of type 2 diabetes and of hyperinsulinaemia independent of obesity on the skeleton stems from several clinical observations in patients
Effect of type 2 diabetes therapies on bone metabolism
Growing medical literature has described the effects of diabetes drugs on bone metabolism and fracture risk. The effect of the most widely used diabetes drugs on bone metabolism is summarised below and in table 2.
How to predict fracture risk?
Clear evidence suggests that people with type 2 diabetes have an increased fracture risk despite BMD values that are generally not in the osteoporotic range. This situation poses considerable challenges for the primary prevention of fragility fractures in these patients since identification of adults at increased fracture risk is primarily on the basis of BMD T scores. Fracture risk assessment methods, such as the WHO Fracture Risk Assessment Tool (FRAX) combine important clinical risk factors
Conclusions
This Review highlights that despite normal to high bone mass, patients with type 2 diabetes have a moderately increased risk of fracture irrespective of sex and race or ethnicity. BMD measurements underestimate skeletal fragility in type 2 diabetes and, therefore, health-care providers should factor the presence of diabetes into their assessment of fracture risk. The pathophysiology of diabetic bone disease is poorly understood, but is certainly multifactorial, associated with a complex
Search strategy and selection criteria
References (137)
- et al.
Advanced glycation endproducts in diabetes and diabetic complications
Endocrinol Metab Clin North Am
(2013) - et al.
Effects of non-enzymatic glycation on cancellous bone fragility
Bone
(2007) - et al.
Etiology of insulin resistance
Am J Med
(2006) - et al.
Glucose Uptake and Runx2 Synergize to Orchestrate Osteoblast Differentiation and Bone Formation
Cell
(2015) - et al.
Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes
Bone
(2013) - et al.
Circulating osteogenic cells: characterization and relationship to rates of bone loss in postmenopausal women
Bone
(2010) - et al.
Visceral adiposity is negatively associated with bone density and muscle attenuation
Am J Clin Nutr
(2015) - et al.
Determinants of bone mineral density in obese premenopausal women
Bone
(2011) - et al.
Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity
Biochem Biophys Res Commun
(1999) - et al.
Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism
Cell
(2010)